Wireframe DNA Origami for the Cellular Delivery of Platinum(II)-Based Drugs

Int J Mol Sci. 2023 Nov 24;24(23):16715. doi: 10.3390/ijms242316715.

Abstract

The DNA origami method has revolutionized the field of DNA nanotechnology since its introduction. These nanostructures, with their customizable shape and size, addressability, nontoxicity, and capacity to carry bioactive molecules, are promising vehicles for therapeutic delivery. Different approaches have been developed for manipulating and folding DNA origami, resulting in compact lattice-based and wireframe designs. Platinum-based complexes, such as cisplatin and phenanthriplatin, have gained attention for their potential in cancer and antiviral treatments. Phenanthriplatin, in particular, has shown significant antitumor properties by binding to DNA at a single site and inhibiting transcription. The present work aims to study wireframe DNA origami nanostructures as possible carriers for platinum compounds in cancer therapy, employing both cisplatin and phenanthriplatin as model compounds. This research explores the assembly, platinum loading capacity, stability, and modulation of cytotoxicity in cancer cell lines. The findings indicate that nanomolar quantities of the ball-like origami nanostructure, obtained in the presence of phenanthriplatin and therefore loaded with that specific drug, reduced cell viability in MCF-7 (cisplatin-resistant breast adenocarcinoma cell line) to 33%, while being ineffective on the other tested cancer cell lines. The overall results provide valuable insights into using wireframe DNA origami as a highly stable possible carrier of Pt species for very long time-release purposes.

Keywords: DNA origami; antitumor drug; cisplatin; drug delivery; platinum compounds.

MeSH terms

  • Breast Neoplasms*
  • Cisplatin / pharmacology
  • DNA / chemistry
  • Female
  • Humans
  • Nanostructures* / chemistry
  • Nucleic Acid Conformation
  • Pharmaceutical Preparations
  • Platinum / pharmacology

Substances

  • phenanthriplatin
  • Cisplatin
  • Platinum
  • Pharmaceutical Preparations
  • DNA

Grants and funding

This research received no external funding.